India is fast emerging as a force to reckon with in the global generics and branded generics arena. What are the changes that drive this market and what are the emerging new marketing strategies that can accelerate ones generic business to capitalize on the demand in global and local markets is elucidated in the article.
The Indian pharmaceutical industry has been undergoing various changes both in terms of approach and in terms of viability of operation. The scenario of the last decade, where almost all known domestic giants were looking at global markets as a major source of business growth, is no longer seen as very viable, given the changing policies that are being adopted by the various governments to protect their own domestic manufacturers.
The Indian pharmaceutical industry has developed over the last decade into a major producer of bulk drugs and is acknowledged as among the top in the world. India has been able to establish technological capability for manufacture and supply of generic drugs. This ‘generics capability’ of India has attracted worldwide attention. A noticeable willingness towards mergers and acquisitions with either a foreign company seeking a stake in an Indian counterpart or vice versa reflects the attractiveness Indian pharmaceutical industry offers.
During the current decade a new visible trend has been emerging in the business approach of both MNCs and Indian pharma majors. With the Indian pharma market remaining highly competitive and driven by price considerations, these companies have now started acknowledging the scenario and have shown a marked flexibility towards adapting to these market realities. India has the second largest population in the world and a growing middle class population. Since the changing economic scenario across the globe offers no insurance to these companies for their business growth sustenance, India has now become the target market given its sustainable growth momentum. The changing governmental health policies which have now enabled better health spend and the favourable shift in the rural income growth is also playing a major role in the way Indian pharmaceutical market is being perceived.
Changing Indian market scenario
Indian pharma market is dominated by the generics product to a great extent. These generics can be classified as branded generics and generic generics. In a country where the patient health spend is at the lowest by the government and health insurance is at the infancy state, the patient has to bear the full expense of his treatment. However the government has played its role in ensuring that the drug prices do not get out of reach of the common patients by bringing in various price control mechanisms.
This has ensured that most of the lifesaving drugs remain in the affordable category to the patients.
The major shift that has been observed in the recent past is the affordability displayed by the rising middle class population. These groups of patients have ensured that the premium pricing tag is acceptable once the quality of service is proved. It is mainly due to this shift one has witnessed a very big growth in corporate hospitals. These hospitals have now occupied the space left vacant by the governmental institutions in treating both the wealthy patients and the upwardly mobile middle class population.
The other influencing factor for the change in the market is the increase in the acceptance of private medical insurance. This sector has been showing a steady growth owing to better advertisement and quality affiliations scope of coverage is currently limited to only in– patients, it is generally expected that over a period of time the outpatient prescriptions also will be covered. Once this happen the need for quality and affordable medicines will increase.
Impact of changing international market scenario
In the last decade there has been a dramatic shift witnessed in the global markets as the need for more affordable generic products grew sharply. This scenario made India as a generic destination and a blessing for people in the under developed countries looking for cheap medicines. The economic slowdown witnessed has been a blessing to the Indian generics as it has been seen by the steady growth enjoyed by this sector. The generic drug companies in India have broad technological and diversified market capabilities. As more and more patents expire, the generic portion of the pharmaceutical market is expected to continue to have increased sales. Indian companies are attempting to tap the generic drug markets of the developed countries. While the spate of products that are likely to go off patent is a major influencing factor in keeping the interest alive in foreign markets the Indian generic manufacturers are becoming more alive to the changing domestic market scenario and are taking steps to respond to the same.
The changing dynamics of the generics market are driving strategic evolution of leading players, with portfolio management, geographic expansion and alliance networks determining success and failure. With cost–containment a focus for all healthcare players, the growth of the generics market is outpacing the branded sector by a considerable margin. Effective portfolio with medical institutions. While the management is critical to future success in the generics market. Maintaining breadth of portfolio and low cost supply is critical for commodity generics players, forcing many players to evaluate higher value generic sectors, thus generating new competitors to brand pharma products. In all the mature markets like US, UK and Germany the generic market is mature and is experiencing high price competition.
Evolving approaches of domestic majors
Since the emerging markets are considered very profitable many of the pharma majors have been adopting different approaches. Recently there has been a spate of mergers and deals that has created lot of interest in the market. These deals and mergers have served the independent needs of each of the partners be it gaining a solid foothold in to Indian pharma market or gaining an assured place in the CRAM space. The Abbott – Piramal deal which helped Abbott to gain the no.1 position with around seven per cent market share is a fine example of such a deal. Many other MNCs are viewing the emerging market with lots of interest and many a promoter families are keen to divest their holdings. As there are a lot of meetings going on around in India between MNCs and Indian family stake holders there are likely hood of many more deals happening. Since contract manufacturing is a big market worldwide estimated to be around US $ 18 to US $ 20 billion , many Indian companies view these deals as a good vehicle to gain share in that space. Biogenerics will be another area of interest as has been seen in the deal between Biocon which is focused in Biogenerics in particular and Mylan.
Another approach that has gained momentum recently is getting in the space of branded generics as also in to the rural generics market. This approach has been found to be popular both with the domestic majors as well as the MNCs. This trend was initiated by Cipla and since has been perfected by many of the domestic majors. With many regional companies and smaller state level enterprises gaining acceptance in the practitioners chamber owing to the price advantage they offered, bigger organizations suffered growth momentum. This has now been addressed with creation of rural field force, with lower employment costs and wider range of generic products that addresses the need for economy. The lower cost of production, economizing distribution costs and reaching higher volumes of field productivity has ensured that this model will be sustained in the days to come and will be one of the business drivers for the industry.
(The author is is a pharma sales and marketing expert with over 30 years of industry experience) (Courtesy: Interlink Insight)